Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Moss – page 8

130 clinical trials in Moss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Moss at a glance
130
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

130 trials in Moss

Open in trial search

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Obesity+1

Not recruiting

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Study of laroprovstat (AZD0780) tablets to lower cholesterol levels in adults with inherited high cholesterol condition (heterozygous familial hypercholesterolemia)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study on Pain Relief for Dental Procedures in Patients with MC1R Mutation Using Lidocaine-Prilocaine Combination and Lidocaine Alone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Epinephrine
  • Sponsor:Pharmavax AS

Giant cell arteritis

Not recruiting

Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Safety and Efficacy Study of Efgartigimod PH20 Subcutaneous in Adults with Primary Immune Thrombocytopenia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Moss

What the registry says about research in the country

01 Rheumatology & Immunology

Clinical research focusing on giant cell arteritis (GCA), exploring innovative therapeutic approaches for this rare inflammatory blood vessel condition. The trials aim to evaluate new treatment combinations that could improve patient outcomes while optimizing glucocorticoid therapy regimens.

  • Inflammatory Vascular Disorders
  • Autoimmune Disease Management
  • Targeted Immunotherapy

These investigations are designed to assess the effectiveness of combining novel biological treatments with traditional steroid therapies, potentially offering new hope for patients managing chronic inflammatory conditions.

02 Therapeutic Innovation

Advanced studies evaluating combination therapy approaches that integrate biological agents with standardized glucocorticoid tapering protocols. This research aims to establish more effective treatment strategies while potentially reducing long-term steroid exposure.

  • Treatment Optimization
  • Steroid-Sparing Strategies
  • Long-term Disease Management

The research focuses on developing sustained remission protocols that could revolutionize the standard of care for inflammatory vascular conditions.

03 Clinical Outcomes

Comprehensive evaluation of treatment efficacy and safety in vascular inflammation, with particular attention to sustained disease remission. The research examines both immediate therapeutic responses and long-term outcomes in patients with inflammatory arterial disease.

  • Remission Assessment
  • Safety Monitoring
  • Quality of Life Impacts

These trials are designed to provide crucial data on the effectiveness of new therapeutic approaches in achieving and maintaining disease control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.